Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09OKZ
|
|||
| Drug Name |
CA4P
|
|||
| Synonyms |
Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr
Click to Show/Hide
|
|||
| Indication | Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 2 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [1] | ||
| Company |
OXiGENE South San Francisco, CA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22O6
|
|||
| Canonical SMILES |
COC1=C(C=C(C=C1)CC(C2=CC(=C(C(=C2)OC)OC)OC)O)O
|
|||
| InChI |
1S/C18H22O6/c1-21-15-6-5-11(8-14(15)20)7-13(19)12-9-16(22-2)18(24-4)17(10-12)23-3/h5-6,8-10,13,19-20H,7H2,1-4H3/t13-/m0/s1
|
|||
| InChIKey |
LGZKGOGODCLQHG-ZDUSSCGKSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.